REG - Haleon PLC - Commencement of £500m Share Buyback Programme

HALEONAnnouncement

Yesterday 10:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260312:nRSL4191Wa&default-theme=true

RNS Number : 4191W  Haleon PLC  12 March 2026

 

Haleon plc: Commencement of £500m Share Buyback Programme

 

12 March 2026: Haleon plc (the "Company", or "Haleon") today announces that,
as set out in the 2025 preliminary full year results announcement on 25
February 2026, it is commencing a share buyback programme to purchase ordinary
shares of £0.01 each in the Company (the "Shares") up to an aggregate
consideration of £500 million (the "Buyback Programme"), in line with its
stated capital allocation priorities, including delivering attractive
shareholder returns.

 

In connection with the Buyback Programme, the Company has entered into an
irrevocable agreement with HSBC Bank plc ("HSBC") for the purchase of Shares.
Under the terms of this agreement, any purchases will be carried out on the
London Stock Exchange, CBoE Equities Europe, and/or Aquis.

 

HSBC will make its trading decisions independently of Haleon, including with
respect to the timing of purchases and during any closed period.

 

Purchases made under the Buyback Programme prior to the Company's 2026 Annual
General Meeting will be effected pursuant to the authority granted by
shareholders at the 2025 AGM. Any purchases made following the 2026 AGM will
be effected pursuant to the authority being sought from shareholders at that
meeting, if approved.

 

The Buyback Programme will commence immediately and end no later than 19
August 2026. All Shares purchased by the Company under the Buyback Programme
will be cancelled and the purpose is to reduce the Company's share capital.

 

Notes

The maximum number of Shares that may be purchased as part of the Buyback
Programme under the Company's existing authority obtained at its Annual
General Meeting held on 28 May 2025 (the "2025 Authority") is 803,994,107,
being the amount of the 2025 Authority not yet utilised as at the date of this
announcement. The Company intends to seek shareholder approval for share
buybacks of up to 10% of the Company's issued share capital at the Company's
upcoming Annual General Meeting to be held in April 2026 (the "2026
Authority").

 

Any purchases of Shares under the Buyback Programme contemplated by this
announcement will be effected within certain pre-set parameters and will be
subject to the terms of the arrangement with HSBC. The Buyback Programme will
operate in accordance with (i) the 2025 Authority or the 2026 Authority (as
applicable); (ii) the assimilated UK Market Abuse Regulation No. 596/2014 and
assimilated Commission Delegated Regulation (EU) 2016/1052 (in each case as
they form part of law of the United Kingdom by virtue of the European Union
(Withdrawal) Act 2018) (as amended) and (iii) Chapter 9 of the UK Financial
Conduct Authority's UK Listing Rules.

 

There is no guarantee that the Buyback Programme will be implemented in full
or of the number of Shares that will be bought back by the Company. The
Company will make further regulatory announcements in respect of purchases of
Shares under the Buyback Programme as they occur.

 

Amanda Mellor

Company Secretary

 

Enquiries

 

 Investors                                                                         Media

 Jo Russell                               +44 7787 392441                          Zoë Bird                              +44 7736 746167
 Rakesh Patel                             +44 7552 484646                          Victoria Durman                       +44 7894 505730

 Email: investor-relations@haleon.com (mailto:investor-relations@haleon.com)       Email: corporate.media@haleon.com (mailto:corporate.media@haleon.com)

 

About Haleon

Haleon (LSE/NYSE: HLN) is a consumer company that is solely focused on better
everyday health. Our people, our brands, our research, our investment and our
innovation are aimed at improving the everyday health of consumers. Our
product portfolio spans six major categories - Oral Health, Vitamins, Minerals
and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and
Therapeutic Skin Health and Other. Our superior brands - such as Advil,
Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and
Voltaren - are trusted by more than one billion consumers and are recommended
by health professionals around the world.

 

For more information, please visit www.haleon.com (http://www.haleon.com/)
.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCKLLBFQXLEBBZ



            Copyright 2019 Regulatory News Service, all rights reserved